Status:
UNKNOWN
1% Metformin Gel-coated Implants and Osteointegration and Crestal Marginal Bone Loss
Lead Sponsor:
Hams Hamed Abdelrahman
Conditions:
Osteointegration
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
Achieving and maintaining a long term osseointegrated dental implant is a golden goal of success in field of dentistry. Osteointegration depends on surface treatment of dental implants. various techni...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Good general periodontal health and maintenance.
- Adequate amount of bone volume at implant site, allowing to perform the dental implant surgery procedure without bone grafting techniques
- Exclusion criteria
- Heavy smokers who smoke more than ten cigarettes per day
- Diabetic patients who have received metformin as antidiabetic drug
- local or systemic conditions that will interfere with routine implant placement (uncontrolled diabetes mellitus or human immune deficiency virus infections, resonance therapy), bone disorders (hyperparathyroidism, osteoporosis, or Paget's disease
- Patients who had subjected to intravenous and/or oral bisphosphonate therapy.
Exclusion
Key Trial Info
Start Date :
September 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2023
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT06031168
Start Date
September 4 2023
End Date
November 30 2023
Last Update
September 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria Faculty of Dentistry
Alexandria, Egypt